Atara Biotherapeutics, Inc. (ATRA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. on April 30, 2026. The filing addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The primary financial metric disclosed is the Company's Market Value of Listed Securities (MVLS), which fell below the required threshold.
Material Changes
- Listing Status: The Company received a notice from Nasdaq stating it no longer meets the $50 million minimum market value for listed securities requirement (Nasdaq Listing Rule 5450(b)(2)(A)).
- Trigger Event: The determination was based on the market value of the Company's listed securities over the last 30 consecutive business days prior to April 30, 2026.
- Current Trading: The notice has no immediate effect on trading; the common stock continues to trade on the Nasdaq Global Select Market under the symbol "ATRA".
Guidance, Outlook, and Risks
- Compliance Period: The Company has been granted 180 calendar days, until October 27, 2026, to regain compliance.
- Regaining Compliance: Compliance is achieved if the MVLS closes at $50 million or more for a minimum of 10 consecutive business days before the Compliance Date.
- Strategic Options: The Company may evaluate options to regain compliance, including applying for a transfer to The Nasdaq Capital Market.
- Delisting Risk: If compliance is not met by the Compliance Date, the Company's securities will be subject to delisting. The Company retains the right to appeal a delisting determination to a Hearings Panel.
- Forward-Looking Statements: Management notes that there can be no assurance the Company will take specific actions or successfully regain compliance.
Investor Verification Checklist
- Verify the current market capitalization and recent stock price trends to assess the likelihood of meeting the $50 million threshold.
- Monitor the Company's stock performance for the next 10 consecutive business days to track progress toward compliance.
- Review the Company's most recent Form 10-K and 10-Q for detailed financial health, cash runway, and operational updates not included in this 8-K.
- Watch for future announcements regarding a potential transfer to The Nasdaq Capital Market or an appeal of a delisting determination.